Attovia Therapeutics files for Nasdaq IPO to fund immune-disease biologics
Tao Fu's San Carlos biotech is seeking an ATTO listing before disclosing price range, share count or valuation.
Read the full articleYou might also wanna read
Two more biotechs, Attovia and Braveheart, join the IPO line
Two more biotechs, Attovia and Braveheart, join the IPO line Phil.Taylor Thu, 16/07/2026 - 10:13
Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron’s Dupixent a
US biotechs turn secretive as they fear competition from rising Chinese industry
US biotechs turn tight-lipped on gene targets and pipelines as China's fast-follower threat intensifies, 20+ founders and investors tell End
endpoints.news·6d agoWhy Q32 Bio Stock Skyrocketed Today
The biotech is advancing a potential treatment for a common autoimmune disease.
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise
Retail traders are watching to see whether ImmunityBio could announce preliminary Q2 revenue, with some speculating that demand for Anktiva
Zhipu Unveils Open-Source AI as $4 Billion Share Sale Lifts Stock
Founder backs open AI access while prioritizing research over short-term monetization amid global AI security debates. Related Stocks: BABA
Comments
Sign in to join the conversation.
No comments yet. Be the first.